Related Experiment Video
Updated: May 8, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Targeting genomic alterations in squamous cell lung cancer
Kalyan Mantripragada1, Humera Khurshid
1The Brown University Oncology Research Group , Providence, RI , USA.
Frontiers in Oncology
|August 13, 2013
Summary
Targeting squamous cell lung cancer requires understanding its complex genomic alterations. This review highlights potential therapeutic targets and pathways for improved patient outcomes.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Squamous cell lung cancer (SqCLC) accounts for significant global mortality.
- Targeted therapies have benefited lung adenocarcinoma patients, but not SqCLC patients.
- Genomic characterization of SqCLC is less advanced than for adenocarcinoma.
Purpose of the Study:
- To review potentially targetable genes and pathways in SqCLC.
- To correlate genomic findings with available and developing therapeutic agents.
- To provide a framework for future clinical investigations in SqCLC.
Main Methods:
- Comprehensive genomic characterization of 178 SqCLC cases.
- Review of existing and investigational therapeutic agents targeting identified genes/pathways.
- Analysis of genomic alterations including driver mutations and copy number variations.
Main Results:
- SqCLC exhibits a more complex and broader range of genomic alterations than lung adenocarcinoma.
- Identified driver mutations and gene copy number alterations contribute to tumor proliferation and survival.
- Several potentially targetable genes and pathways have been identified.
Conclusions:
- Understanding SqCLC's complex genomic landscape is crucial for developing effective therapies.
- Targeting identified genetic alterations offers promise for therapeutic gains in SqCLC.
- Collaboration is essential for rapid translation of research findings into clinical benefits for SqCLC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...